Status:
UNKNOWN
Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia
Lead Sponsor:
Puren Hospital Affiliated to Wuhan University of Science and Technology
Collaborating Sponsors:
Shanghai University
Qingdao Co-orient Watson Biotechnology group co. LTD
Conditions:
COVID-19
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
PHASE2
Brief Summary
The COVID-19 pneumonia has grown to be a global public health emergency since patients were first detected in Wuhan, China, in December 2019, which spread quickly to worldwide and presented a serious ...
Detailed Description
Since December 2019, novel coronavirus disease 2019 (COVID-19) in Wuhan has been fierce and spread rapidly. As of 24:00 on March 4, 2020, China has reported a total of 80567 confirmed cases, 5952 exis...
Eligibility Criteria
Inclusion
- Male or female, 18 years old ≤ age ≤ 75years old;
- CT image is characteristic of 2019 novel coronavirus pneumonia;
- Laboratory confirmation of 2019-nCoV infection by reverse transcription polymerase chain reaction (RT-PCR);
- In compliance with the 2019-nCoV pneumonia diagnosis standard (according to the novel coronavirus infection pneumonia diagnosis and treatment program (Trial Implementation Version 6) issued by the National Health and Medical Commission, and WHO 2019 new coronavirus guidelines standards): (A) increased breathing rate (≥30 beats / min), difficulty breathing, cyanosis of the lips; (B) in resting state, means oxygen saturation ≤93%; (C) partial pressure of arterial oxygen (PaO2) / Fraction of inspired oxygen (FiO2) ≤300 mmHg (1mmHg = 0.133kPa);
- Participant or the authorized agent signed the informed consent form.
- Agree to collect clinical samples.
Exclusion
- Malignant disease in the past five years;
- Participant with no hope of survival were clinically predicted and only received hospice care, or those who were in a deep coma and did not respond to supportive treatment measures within three hours of admission.
- Participant who are participating in other clinical trials or who have participated in other clinical trials within 3 months.
- Cases of severe shock and respiratory failure.
Key Trial Info
Start Date :
February 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2020
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04339660
Start Date
February 1 2020
End Date
June 30 2020
Last Update
April 9 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Puren Hospital Affiliated to Wuhan University of Science and Technology
Wuhan, Hubei, China, 430081